Today, artificial intelligence is no longer a strange word for people. We have heard of them in all walks of life. The abbreviation for artificial intelligence (ArTIficial Intelligence) is AI. It is a new technical science that studies and develops theories, methods, techniques, and applications that simulate, extend, and extend human intelligence. "Artificial intelligence is a revolution comparable to the 'industrial revolution', and it will bring a very different experience in many fields." Baidu founder Li Yanhong once said that in the future 20 to 50 years in China, artificial intelligence will become an important economic growth. One of the driving forces. From unmanned warehouses to artificial intelligence customer service to automated driving technology, even medical diagnosis can be assisted... Today, many pharmaceutical giants are also experimenting with the AI+ pharmaceutical model, which has sprung up. In 2015, Merck worked with Atomwise in the United States, and its groundbreaking AtomNet technology platform can be logically thought like a human medicinal chemist to speed up drug development. Mainly targeted at the effectiveness and safety of new drugs. In 2016, Johnson & Johnson reached a new drug research and development cooperation with British AI technology development and application company BenevolentAI. BenevolentAI is known as Europe's most valuable artificial intelligence startup, and its core technology is an artificial intelligence system called JACS. JACS extracts a large amount of data from papers and clinical trials in the operation, extracts knowledge that promotes drug development, and proposes new verifiable hypotheses to accelerate the development of new drugs. Johnson & Johnson can use this to develop new drugs. In 2016, Pfizer worked with IBM to assist in the development of immunological oncology drugs. IBM's Watson robots can quickly analyze large amounts of textual data, use large amounts of laboratory data, and clinical reports to find potential drugs. Pfizer also brings VR technology to the field of new drug research and development, exploring the possibility of VR technology in drug development. ...... In general, AI subverts the R&D model of traditional pharmaceutical companies, which can improve R&D efficiency, reduce the risk of manual R&D, and reduce R&D time, thus reducing R&D costs. According to TechEmergence's research report, artificial intelligence can increase the success rate of new drug development from 12% to 14%, and its 2% increase means helping the industry to reduce the cost. Industry insiders predict that in the future, if the AI ​​is helped, the price of medicines may also decrease. On the one hand, the development time of new drugs is shortened, the speed of drug listing is accelerated, and enterprises can obtain more patent protection years; on the other hand, the success rate of clinical trials is increased, and the cost of medicines naturally decreases. This means that pharmaceutical companies will not have to pass on more clinical failure costs to consumers. The benefits of AI+ pharmaceuticals are obvious. However, the current layout is mainly for multinational pharmaceutical companies. China's state-owned enterprises are still temporarily lacking in the use of artificial intelligence. The industry said that there is still a big gap between us and developed countries, the original theoretical foundation is weak, major products and systems are missing, and talent supply is insufficient. In recent years, in order to encourage the development of artificial intelligence, China has also made a lot of relevant policy support. For example, in 2017, China issued the “New Generation Artificial Intelligence Development Plan†and other policy documents, which effectively promoted important breakthroughs in key technologies and applications such as industrial robots. I believe that in the future, there will be pharmaceutical companies in China that use the AI ​​model to develop new drugs. In general, the development of new drugs is a complex process. With the help of AI, it can save a lot of cost and time for pharmaceutical companies. This is also the value of AI+ pharmaceuticals. However, many people worry that AI will replace pharmaceutical R&D personnel in the future. The author believes that artificial intelligence can only be regarded as an assistant to the pharmaceutical industry, helping pharmaceutical R&D personnel to better accomplish difficult or difficult things without threats. Mini Displayport Splitter,Dp Cable Splitter,Best Displayport Splitter,Dp Port Splitter Dongguan Tuojun Electronic Technology Co., Ltd , https://www.fibercablessupplier.com